Several novel therapeutic agents have demonstrated improvement of overall survival and further patient relevant endpoints in the setting of castration-resistant prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Nevertheless, two questions have become increasingly relevant: are there any prognostic or predictive markers that could ease clinical decision-making using risk stratification and risk-adapted treatment in order to provide a benefit for the patient? Furthermore, against the background of increasing possibilities of therapy sequencing in clinical practice and in the clinical trial landscape in castration-resistant prostate cancer, does an isolated evaluation of overall survival reliably mirror the benefit attributable to a single compound? To address both these questions, suitable parameters serving as surrogates for intermediate and long-term endpoints and reflecting individual benefit, respectively, need to be identified and proven.
Aziz A, Kempkensteffen C, May M, Lebentrau S, Burger M, Chun FK, Brookman-May S. Are you the author?
Department of Urology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
Reference: Expert Rev Anticancer Ther. 2015 Jun;15(6):649-66.